Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced that Ron Bentsur, Chairman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, to discuss the development of precision medicines for serious conditions in oncology.

Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 42nd Annual J.P. Morgan Healthcare Conference, as follows:

Date	Monday, January 08, 2024
Time	04:30 PM - 05:10 PM PT
Webcast Link	https://jpmorgan.metameetings.net/events/healthcare24/sessions/50117-nuvectis-pharma-inc/webcast?gpu_only=true&kiosk=true

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule currently in a Phase 1b clinical trial investigating the activity of NXP800 as a potential treatment for platinum resistant, ARID1a-mutated ovarian carcinoma. The U.S. Food and Drug Administration (“FDA”) granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor. The NXP900 Investigational New Drug Application has been cleared by the FDA and a Phase 1a dose escalation study is ongoing.

Company Contact

Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
rbentsur@nuvectis.com

Media Relations Contact

Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com 

When will Ron Bentsur present at the 42nd Annual J.P. Morgan Healthcare Conference?

Ron Bentsur will present on Monday, January 8, 2024, from 04:30 PM to 05:10 PM PT.

What is the focus of Nuvectis Pharma, Inc. (NVCT)?

Nuvectis Pharma, Inc. is focused on the development of innovative precision medicines for serious conditions in oncology.

Where can I watch the webcast of the presentation?

The webcast link for the presentation is https://jpmorgan.metameetings.net/events/healthcare24/sessions/50117-nuvectis-pharma-inc/webcast?gpu_only=true&kiosk=true